Merck, Pfizer trot out more support for latecomer SGLT2 candidate ertugliflozin

10th June 2017 Uncategorised 0

Sanofi’s Toujeo has plenty of competition in the basal insulin market, but new real-world data shows it may outdo its peers at cutting the risk of hypoglycemia for older patients. And Sanofi’s planning three real-world follow-ups, a “major shift” from its usual data approach.

More: Merck, Pfizer trot out more support for latecomer SGLT2 candidate ertugliflozin
Source: fierce